What is the basis? Does the applicable indirect cost rate apply to all direct costs?*If you use our federally negotiated indirect cost rate, the rate is applied to a base figure known as modified total direct cost (MTDC), which represents a lower total direct cost (TDC): the spatial survey is used to develop UC Davis` R&A proposal. The functional use of space is the most critical part of the R&A proposal. As a result, federal auditors are carefully reviewing the results of the investigation. The current rates that have been set for Funding from the State of California, with the exception of funding by the CDFA, in PRPP Memo 17-07 and in accordance with UCOP`s April 15, 2020 Update, have been revised as follows. An ETP, a non-federal agency that provides a sub-grant to a sub-intentional person for the carrying out of part of a federal project, is not authorized to apply unilateral restrictions on indirect cost coverage, pursuant to 2 CFR 200.331. Studies that are not fully funded by one or more for-profit companies, but which otherwise meet the above definition of “clinical trial”, do not qualify for the application of the indirect rate of 26% and are considered indirect costs negotiated by the Confederation for “Other sponsored projects”. Definition of “clinical trial” for the purpose of using 26% R&A: the controlled clinical trial of new human drugs, products, treatments or diagnostics or comparisons of drugs, products, treatments or diagnostics authorized to assess their safety, efficacy, benefits, costs, side effects and/or results fully funded by one or more for-profit companies. UCOP concluded that there was no difference between clinical trials initiated by the sponsor and those initiated by the test physician. Both types of clinical trials, as defined here, are subject to the same indirect cost rate as applied to the total direct cost.
There will therefore be three (3) months at a rate of 24% and nine (9) months at a rate of 24.5%.